MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Conditions: Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Fallopian Tube Carcinosarcoma; Recurrent Female Reproductive System Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Carcinosarcoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Carcinosarcoma; Refractory Fallopian Tube Carcinoma; Refractory Female Reproductive System Carcinoma; Refractory Ovarian Carcinoma; Refractory Primary Peritoneal Carcinoma

Interventions: Biological: Autologous MUC1-activated T-cells; Drug: Bendamustine; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Cyclophosphamide; Procedure: Echocardiography; Procedure: Leukapheresis; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Procedure: Positron Emission Tomography

Sponsors: Mayo Clinic

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 2, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments